XADAGO Market Size, Forecast, and Market Insight - 2032
상품코드:1462258
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
앞으로 몇 년 동안 파킨슨병의 시장 시나리오는 전 세계적으로 광범위한 연구와 의료비 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, XADAGO의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다.
파킨슨병에 대한 다른 신흥 제품은 XADAGO에 치열한 시장 경쟁을 가져올 것으로 예상되며, 가까운 장래에 후발 신흥 치료제가 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.
XADAGO가 파킨슨병에서 효과를 발휘하는 정확한 메커니즘은 아직 밝혀지지 않았지만, XADAGO는 모노아민 산화효소 B(MAO-B) 억제제이며, MAO-B의 활성을 억제함으로써 도파민의 이화 작용을 억제하고 도파민 농도를 증가시켜 뇌의 도파민 작용을 증가시키는 것으로 알려져 있습니다. 뇌 내 도파민 활성도가 증가한다고 알려져 있습니다.
이 보고서는 주요 7개국 파킨슨병 치료제 XADAGO 시장에 대해 조사했으며, 시장 개요, 경쟁 상황, 2032년까지의 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.
목차
제1장 보고서 소개
제2장 파킨슨병의 XADAGO 개요
제품 상세
임상 개발
규제 마일스톤
기타 발달 활동
제품 프로파일
제3장 경쟁 상황(출시된 치료법)
제4장 경쟁 상황(후기 단계 새로운 치료법)
제5장 XADAGO 시장 평가
파킨슨병의 XADAGO 시장 전망
주요 7개국 분석
주요 7개국의 파킨슨병 치료의 XADAGO 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 보고서 구입 옵션
ksm
영문 목차
영문목차
"XADAGO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about XADAGO for Parkinson's disease in the seven major markets. A detailed picture of the XADAGO for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XADAGO for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XADAGO market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Drug Summary:
XADAGO tablets contain safinamide as the mesylate salt. Safinamide mesylate is (S)-2-[[4-[(3-fluorophenyl) methoxy] phenyl] methyl] aminopropanamide methanesulfonate (1:1). XADAGO is available as 50 mg and 100 mg film-coated tablets for oral administration. Each tablet contains 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg, respectively, of the safinamide-free base. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide (red), magnesium stearate, microcrystalline cellulose, polyethylene glycol 6000, potassium aluminum silicate, and titanium dioxide.
Dosage and administration
It is started with 50 mg administered orally once daily at the same time of day; after 2 weeks, the dose may be increased to 100 mg once daily, based on individual need and tolerability.
In hepatic impairment, patient dosage should not exceed 50 mg once daily. It is contraindicated in patients with severe hepatic impairment.
Mechanism of action
The precise mechanism by which XADAGO exerts its effect in Parkinson's disease is unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the XADAGO description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
Elaborated details on XADAGO regulatory milestones and other development activities have been provided in this report.
The report also highlights the XADAGO research and development activities in Parkinson's disease across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around XADAGO.
The report contains forecasted sales of XADAGO for Parkinson's disease till 2032.
Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
The report also features the SWOT analysis with analyst views for XADAGO in Parkinson's disease.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
XADAGO Analytical Perspective by DelveInsight
In-depth XADAGO Market Assessment
This report provides a detailed market assessment of XADAGO for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
XADAGO Clinical Assessment
The report provides the clinical trials information of XADAGO for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XADAGO dominance.
Other emerging products for Parkinson's disease are expected to give tough market competition to XADAGO and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XADAGO in Parkinson's disease.
Our in-depth analysis of the forecasted sales data of XADAGO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XADAGO in Parkinson's disease.
Key Questions:
What is the product type, route of administration and mechanism of action of XADAGO?
What is the clinical trial status of the study related to XADAGO in Parkinson's disease and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XADAGO development?
What are the key designations that have been granted to XADAGO for Parkinson's disease?
What is the forecasted market scenario of XADAGO for Parkinson's disease?
What are the forecasted sales of XADAGO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to XADAGO for Parkinson's disease?
Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?
